Rein Therapeutics (NASDAQ:RNTX) Director Rickenbach Josef Von Buys 15,950 Shares

Rein Therapeutics Inc. (NASDAQ:RNTX) Director Rickenbach Josef Von bought 15,950 shares of Rein Therapeutics stock in a transaction dated Friday, May 22nd. The stock was acquired at an average cost of $1.05 per share, for a total transaction of $16,747.50. Following the purchase, the director directly owned 34,824 shares in the company, valued at approximately $36,565.20. The trade was a 84.51% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Rein Therapeutics Price Performance

Rein Therapeutics stock opened at $1.11 on Friday. The company’s 50 day simple moving average is $1.33 and its 200 day simple moving average is $1.31. Rein Therapeutics Inc. has a fifty-two week low of $0.95 and a fifty-two week high of $2.18. The firm has a market capitalization of $94.95 million, a price-to-earnings ratio of -0.58 and a beta of 1.42.

Rein Therapeutics (NASDAQ:RNTX) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.30. As a group, analysts predict that Rein Therapeutics Inc. will post -1.63 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of RNTX. Geode Capital Management LLC acquired a new position in Rein Therapeutics during the second quarter valued at approximately $344,000. Northwestern Mutual Wealth Management Co. bought a new position in Rein Therapeutics in the second quarter valued at approximately $68,000. Cable Car Capital LP bought a new position in Rein Therapeutics in the second quarter valued at approximately $588,000. Gagnon Securities LLC lifted its stake in Rein Therapeutics by 218.8% in the third quarter. Gagnon Securities LLC now owns 228,692 shares of the company’s stock valued at $262,000 after buying an additional 156,947 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Rein Therapeutics by 32.2% in the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock valued at $1,338,000 after buying an additional 284,300 shares in the last quarter. Institutional investors and hedge funds own 90.89% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Rein Therapeutics to a “sell” rating in a report on Saturday, May 16th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $8.00.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.